Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) had its price objective decreased by Jefferies Financial Group from $77.00 to $28.00 in a research report report published on Thursday,Benzinga reports. Jefferies Financial Group currently has a buy rating on the biopharmaceutical company’s stock.
Several other analysts have also recently commented on RARE. Guggenheim decreased their price target on shares of Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating for the company in a report on Tuesday, August 4th. TD Cowen dropped their price objective on shares of Ultragenyx Pharmaceutical from $49.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday. Wedbush cut their target price on shares of Ultragenyx Pharmaceutical from $30.00 to $23.00 and set a “neutral” rating for the company in a research report on Thursday. JPMorgan Chase & Co. lowered shares of Ultragenyx Pharmaceutical from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $80.00 to $36.00 in a research note on Thursday. Finally, Wells Fargo & Company downgraded shares of Ultragenyx Pharmaceutical from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $50.00 to $18.00 in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $36.63.
Read Our Latest Stock Report on Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Trading Up 3.0%
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The firm had revenue of $214.00 million during the quarter, compared to analyst estimates of $183.08 million. During the same period last year, the company posted ($1.17) EPS. The business’s quarterly revenue was up 28.5% compared to the same quarter last year. Equities analysts forecast that Ultragenyx Pharmaceutical will post -3.98 earnings per share for the current year.
Insider Activity at Ultragenyx Pharmaceutical
In other news, Director Corsee Sanders sold 2,000 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $25.05, for a total transaction of $50,100.00. Following the transaction, the director owned 21,095 shares in the company, valued at $528,429.75. This represents a 8.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Karah Parschauer sold 1,899 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $24.62, for a total transaction of $46,753.38. Following the transaction, the executive vice president owned 94,462 shares in the company, valued at $2,325,654.44. This represents a 1.97% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 5.20% of the company’s stock.
Hedge Funds Weigh In On Ultragenyx Pharmaceutical
Institutional investors have recently bought and sold shares of the stock. Parallel Advisors LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 778.4% during the 1st quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 1,440 shares in the last quarter. Leonteq Securities AG raised its stake in shares of Ultragenyx Pharmaceutical by 288.5% in the 1st quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 1,333 shares in the last quarter. Versant Capital Management Inc raised its stake in shares of Ultragenyx Pharmaceutical by 662.9% in the 2nd quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 1,001 shares in the last quarter. Danske Bank A S acquired a new stake in Ultragenyx Pharmaceutical in the 3rd quarter worth approximately $39,000. Finally, EverSource Wealth Advisors LLC lifted its holdings in Ultragenyx Pharmaceutical by 573.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 1,845 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors.
Key Ultragenyx Pharmaceutical News
Here are the key news stories impacting Ultragenyx Pharmaceutical this week:
- Positive Sentiment: Several analysts still see substantial potential upside after the selloff. Barclays maintained an “overweight” rating with a $32 price target, while Jefferies, Citigroup, TD Cowen, Canaccord Genuity, Cantor Fitzgerald and HC Wainwright retained bullish ratings despite sharply reducing their targets.
- Positive Sentiment: Ultragenyx is evaluating “significant” cost reductions following the trial failure, which could help preserve cash and improve the company’s financial outlook. Investors are also focusing on its existing commercial rare-disease portfolio. Ultragenyx to weigh significant cost cuts as Angelman drug fails key study
- Positive Sentiment: Unusually heavy call-option activity and speculation that Ultragenyx could become an acquisition target provide potential—but highly speculative—support for the stock. Ultragenyx potential M&A target
- Neutral Sentiment: Analyst views are increasingly divided. Goldman Sachs lowered its target to $19 and moved to “neutral,” while Barclays remains “overweight” at $32. Jefferies and Citi kept “buy” ratings but reduced targets to $28. The wide range reflects uncertainty over Ultragenyx’s post-trial growth prospects.
- Negative Sentiment: RBC downgraded the company to “hold,” while Bank of America, JPMorgan, Wells Fargo, Baird, Evercore, William Blair and others also reduced ratings or targets. Baird and Evercore now see only limited upside, signaling diminished confidence in the pipeline.
- Negative Sentiment: The Angelman syndrome failure creates greater dependence on Ultragenyx’s existing products and other pipeline programs. The company is weighing the future of the program, adding uncertainty around research spending, revenue growth and long-term valuation. Ultragenyx Angelman syndrome trial failure
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.
The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.
Featured Stories
- Five stocks we like better than Ultragenyx Pharmaceutical
- Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key Signal
- Is Duolingo the Next Netflix-Style Comeback Story?
- GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue
- GTA VI’s Console Problem Isn’t Take-Two’s Problem
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
